drugset / Trial / NCT00452907

ACT MALI: Treatment of Malaria Based on Combination Therapies

NCT00452907

Phase 4 Completed 780 enrolled Sanofi
RandomizedParallel-groupOpen-labelTreatment

Summary

Test the hypothesis that repeated administration of Artesunate/Amiodaquine, Artesunate/Sulfadoxine-Pyrimethamine and Arthemeter-Lufemantrine for the treatment of consecutive episodes of uncomplicated malaria reduces the incidence of uncomplicated falciparum malaria and malaria attributable anemia

Timeline

Start
2005-07
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Artesunate Small molecule 50 mg Oral
Comparator Sulfadoxine-pyrimethamine Small molecule 500 mg Oral
Comparator arthemether Unknown 20 mg Oral
Comparator lumefantrine Small molecule 120 mg Oral
Comparator pyrimethamine Small molecule 25 mg Oral

Indications